Teva Pharmaceutical says to hit EPS of $2.30 in '07
TEL AVIV, Aug 1 (Reuters) - Teva Pharmaceutical Industries (TEVA.O) (TEVA.TA) said on Wednesday it expects to hit the upper end of its full-year 2007 earnings per share estimate range of $2.20 to $2.30.
Israel-based Teva, the world's largest generic drugmaker, in May raised its EPS estimate for 2007 to $2.20 to $2.30 from $2.07 to $2.19.
"We are confident and optimistic that we will reach the high end of this range. We will touch $2.30," Shlomo Yanai, Teva's president and chief executive officer, told a news conference to announce second-quarter financial results.
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
